Abstract
Neuroblastoma (NB) is the most common pediatric solid malignant tumor derived from the sympathetic nervous system. High-risk NB is still one of the most difficult tumors to cure, with only 40% long-term survival despite intensive multimodal therapy. The clinical presentation and treatment response of advanced NB, which results in relapse and a refractory state after a good response to the initial chemotherapy, suggests that cancer stem cells (CSCs) likely exist in NB tumors. Putative CSCs using primary tumor sphere formation from NB patients were reported previously, and several molecules will be elucidated from the tumor sphere to develop CSC-targeting therapies. Recently, our group reported that a CSC marker for several malignancies, CD133, and the stemness-related polycomb BMI1 have functions to repress NB cell differentiation. Depletion of CD133 or BMI1 effectively induced neurite elongation and marker molecules for differentiation in NB cells. Of note, CD133-related NB cell differentiation and RET (rearranged during transfection) repression were considerably dependent on p38MAPK and phosphoinositide 3-kinase (PI3K)/AKT pathways. Intriguingly, both CD133 and BMI1 also have a role in xenograft tumor formation and tumor sphere formation. These observations suggest that CD133 and BMI1 may be candidates for the development of CSC-targeting therapies for refractory NB patients.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Reya T, Morrison SJ, Clarke MF, Weissman IL . Stem cells, cancer, and cancer stem cells. Nature 2001;414:105–11.
Dick JE . Stem cell concepts renew cancer research. Blood 2008;112:4793–807.
Visvader JE, Lindeman GJ . Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755–68.
Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66:9339–44.
Tang C, Ang BT, Pervaiz S . Cancer stem cell: target for anti-cancer therapy. FASEB J 2007;21:3777–85.
Illmensee K, Mintz B . Totipotency and normal differentiation of single teratocarcinoma cells cloned by injection into blastocysts. Proc Natl Acad Sci USA 1976;73:549–53.
Bonnet D, Dick JE . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730–7.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983–8.
Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396–401.
O’Brien CA, Pollett A, Gallinger S, Dick JE . A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106–10.
Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111–5.
Joo KM, Kim SY, Jin X, et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 2008;88:808–15.
Huang EH, Hynes MJ, Zhang T, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009;69:3382–9.
van Noesel MM, Versteeg R . Pediatric neuroblastomas: genetic and epigenetic ‘danse macabre’. Gene 2004;325:1–15.
Brodeur GM . Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203–16.
Evans AE, D’Angio GJ, Randolph J . A proposed staging for children with neuroblastoma. Children’s cancer study group A. Cancer 1971;27:374–8.
Maris JM, Hogarty MD, Bagatell R, Cohn SL . Neuroblastoma. Lancet 2007;369:2106–20.
Yu AL, Gilman AL, Ozkaynak MF, et al.; Children’s Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324–34.
Walton JD, Kattan DR, Thomas SK, et al. Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia 2004;6:838–45.
Ross RA, Spengler BA, Domènech C, Porubcin M, Rettig WJ, Biedler JL . Human neuroblastoma I-type cells are malignant neural crest stem cells. Cell Growth Differ 1995;6:449–56.
Hansford LM, McKee AE, Zhang L, et al. Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res 2007;67:11234–43.
Smith KM, Datti A, Fujitani M, et al. Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens. EMBO Mol Med 2010;2:371–84.
Grinshtein N, Datti A, Fujitani M, et al. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res 2011;71:1385–95.
Corbeil D, Fargeas CA, Huttner WB . Rat prominin, like its mouse and human orthologues, is a pentaspan membrane glycoprotein. Biochem Biophys Res Commun 2001;285:939–44.
Maw MA, Corbeil D, Koch J, et al. A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. Hum Mol Genet 2000;9:27–34.
Zacchigna S, Oh H, Wilsch-Bräuninger M, et al. Loss of the cholesterol-binding protein prominin-1/CD133 causes disk dysmorphogenesis and photoreceptor degeneration. J Neurosci 2009;29:2297–308.
Bhatia M . AC133 expression in human stem cells. Leukemia 2001;15:1685–8.
Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1:313–23.
Ma S, Tang KH, Chan YP, et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010;7:694–707.
Takenobu H, Shimozato O, Nakamura T, et al. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene 2011;30:97–105.
Mahller YY, Williams JP, Baird WH, et al. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS ONE 2009;4:e4235.
Shmelkov SV, Jun L, St Clair R, et al. Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood 2004;103:2055–61.
Schiapparelli P, Enguita-Germán M, Balbuena J, Rey JA, Lázcoz P, Castresana JS . Analysis of stemness gene expression and CD133 abnormal methylation in neuroblastoma cell lines. Oncol Rep 2010;24:1355–62.
Baba T, Convery PA, Matsumura N, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009;28:209–18.
Yi JM, Tsai HC, Glöckner SC, et al. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res 2008;68:8094–103.
Hanahan D, Weinberg RA . The hallmarks of cancer. Cell 2000;100:57–70.
Sparmann A, van Lohuizen M . Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006;6:846–56.
Rajasekhar VK, Begemann M . Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective. Stem Cells 2007;25:2498–510.
Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M . Stem cells and cancer; the polycomb connection. Cell 2004;118:409–18.
Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K . EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003;22:5323–35.
Nowak K, Kerl K, Fehr D, et al. BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res 2006;34:1745–54.
Cui H, Ma J, Ding J, Li T, Alam G, Ding HF . Bmi-1 regulates the differentiation and clonogenic self-renewal of I-type neuroblastoma cells in a concentration-dependent manner. J Biol Chem 2006;281:34696–704.
Wang Z, Park HJ, Carr JR, et al. FoxM1 in tumorigenicity of the neuroblastoma cells and renewal of the neural progenitors. Cancer Res 2011;71:4292–302.
Ochiai H, Takenobu H, Nakagawa A, et al. Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma. Oncogene 2010;29:2681–90.
Acknowledgements
The author thanks Daniel Mrozek, Medical English Service, for editorial assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kamijo, T. Role of stemness-related molecules in neuroblastoma. Pediatr Res 71, 511–515 (2012). https://doi.org/10.1038/pr.2011.54
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/pr.2011.54
This article is cited by
-
ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors
BMC Cancer (2023)
-
Roniciclib down-regulates stemness and inhibits cell growth by inducing nucleolar stress in neuroblastoma
Scientific Reports (2020)
-
MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2
Journal of Experimental & Clinical Cancer Research (2019)
-
A c-Myc-regulated stem cell-like signature in high-risk neuroblastoma: A systematic discovery (Target neuroblastoma ESC-like signature)
Scientific Reports (2017)
-
Perfused Three-dimensional Organotypic Culture of Human Cancer Cells for Therapeutic Evaluation
Scientific Reports (2017)
